Hailong Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hailong Luo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Bo Tang
Department of Vascular Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 shared publicationsHaolong Zhang
Department of Vascular Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 shared publicationsJian Fu
Department of Vascular Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications- Yikuan Chen
Department of Vascular Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications Ai-Ying Mm Jiang
Department of Respiratory Medicine, The Affiliated Hongqi Hospital of Mudanjiang Medical University
1 shared publication- Chunjuan Li
Affiliation School of Computer Science and Engineering, Changchun University of Technology, Changchun, China
1 shared publication
Latest Publications
- 6 November 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
Comparing Sac Embolization and Inferior Mesenteric Artery Embolization in Preventing Type II Endoleaks Post-EVAR
Objective: To compare the efficacy of sac embolization (SACE) versus inferior mesenteric artery embolization (IMAE) in preventing persistent Type II endoleaks (pT2EL) and promoting aneurysmal sac shrinkage following endovascular aneurysm repair (EVAR) in high-risk patients. Methods: From January 2018 to December 2022, 273 EVAR patients were screened, and 75 with patent IMA and high T2EL risk were included. Patients were divided into 2 groups: EVAR with IMAE (33 cases) and EVAR with SACE (42 cases). The primary endpoint was the incidence of pT2EL. Secondary endpoints included sac enlargement, shrinkage, and T2EL-related reintervention. Kaplan-Meier analysis and multivariate regression were used for comparisons. Results: SACE was associated with a significantly lower incidence of pT2EL than IMAE (2.4% vs 21.2%, p=0.007; HR: 0.140, 95% CI: 0.034–0.578) and a higher rate of sac shrinkage (>5 mm reduction) (83.3% vs 57.6%, p=0.005; HR: 2.272, 95% CI: 1.286–4.014). Sac enlargement (>5 mm) occurred only in the IMAE group (6.1%, p=0.097). SACE required less contrast use (113.7 ± 24.5 vs 140.5 ± 29.6 mL, P < 0.001) and exhibited a trend toward fewer reinterventions. No ruptures or AAA-related deaths occurred in either group. Conclusion: SACE is more effective than IMAE in preventing pT2EL and promoting sac shrinkage in high-risk EVAR patients. These results support SACE as the preferred adjunctive strategy, warranting further multicenter studies with longer follow-up to confirm its benefits and optimize techniques. Clinical Impact: This study provides comparative evidence on two adjunctive techniques used during EVAR for high-risk patients. Sac embolization (SACE) demonstrated a lower incidence of persistent type II endoleaks and a higher rate of aneurysm sac shrinkage compared with inferior mesenteric artery embolization (IMAE), with reduced contrast use and comparable safety. These findings suggest that SACE may offer a more effective and practical approach for type II endoleak prevention and sac regression, potentially improving long-term outcomes and procedural efficiency in EVAR practice.
- 6 November 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
Comparing Sac Embolization and Inferior Mesenteric Artery Embolization in Preventing Type II Endoleaks Post-EVAR
Objective: To compare the efficacy of sac embolization (SACE) versus inferior mesenteric artery embolization (IMAE) in preventing persistent Type II endoleaks (pT2EL) and promoting aneurysmal sac shrinkage following endovascular aneurysm repair (EVAR) in high-risk patients. Methods: From January 2018 to December 2022, 273 EVAR patients were screened, and 75 with patent IMA and high T2EL risk were included. Patients were divided into 2 groups: EVAR with IMAE (33 cases) and EVAR with SACE (42 cases). The primary endpoint was the incidence of pT2EL. Secondary endpoints included sac enlargement, shrinkage, and T2EL-related reintervention. Kaplan-Meier analysis and multivariate regression were used for comparisons. Results: SACE was associated with a significantly lower incidence of pT2EL than IMAE (2.4% vs 21.2%, p=0.007; HR: 0.140, 95% CI: 0.034–0.578) and a higher rate of sac shrinkage (>5 mm reduction) (83.3% vs 57.6%, p=0.005; HR: 2.272, 95% CI: 1.286–4.014). Sac enlargement (>5 mm) occurred only in the IMAE group (6.1%, p=0.097). SACE required less contrast use (113.7 ± 24.5 vs 140.5 ± 29.6 mL, P < 0.001) and exhibited a trend toward fewer reinterventions. No ruptures or AAA-related deaths occurred in either group. Conclusion: SACE is more effective than IMAE in preventing pT2EL and promoting sac shrinkage in high-risk EVAR patients. These results support SACE as the preferred adjunctive strategy, warranting further multicenter studies with longer follow-up to confirm its benefits and optimize techniques. Clinical Impact: This study provides comparative evidence on two adjunctive techniques used during EVAR for high-risk patients. Sac embolization (SACE) demonstrated a lower incidence of persistent type II endoleaks and a higher rate of aneurysm sac shrinkage compared with inferior mesenteric artery embolization (IMAE), with reduced contrast use and comparable safety. These findings suggest that SACE may offer a more effective and practical approach for type II endoleak prevention and sac regression, potentially improving long-term outcomes and procedural efficiency in EVAR practice.
- Open Access
- 1 October 2023
- Published by SAGE Publications in Science Progress
- Vol. 106 (4)
Endovascular treatment of systematic isolated mesenteric artery dissection with a patent false lumen: Bare stents alone versus stent-assisted coiling
Objectives: Bare stent treatment and bare stent-assisted coiling treatment have not been directly compared in symptomatic isolated superior mesenteric artery dissection with a patent false lumen. Thus, we compared the early and mid-term outcomes of bare stent treatment and bare stent-assisted coiling treatment to determine the most effective remedy for patients with this condition. Methods: Consecutive patients diagnosed with systematic isolated superior mesenteric artery dissection with a patent false lumen admitted to the study hospital between January 2016 and December 2021 were enrolled in this retrospective study. Their demographic data, clinical findings, treatment options, early outcomes, and follow-up results were analyzed. Results: A total of 85 patients (83 men) were included. 34.1% (n = 29) adopted bare stent treatment and 65.9% (n = 56) underwent bare stent-assisted coiling treatment. The symptoms were relieved in all patients (100%) with bare stent treatment and bare stent-assisted coiling treatment. There was no significant difference in the length of hospital stay between the two endovascular treatments ( p = 0.354). The cumulative complete remodeling rate was 100% in bare stent-assisted coiling treatment vs. 70.4% in bare stent treatment ( p < 0.0001). The prevalence of adverse events for abdominal pain recurrence (none in BST or bare stent-assisted coiling treatment), and formation of the aneurysm (two in bare stent treatment, and none in bare stent-assisted coiling treatment) showed no significant difference at follow-up. Conclusion: Both bare stent treatment and bare stent-assisted coiling treatment for symptomatic isolated superior mesenteric artery dissection with a patent false lumen have the same satisfying early outcome. In the midterm follow-up, bare stent-assisted coiling treatment has the higher cumulative complete remodeling rate which could be prioritized to treat this condition.
- 1 October 2023
- Published by SAGE Publications in Science Progress
- Vol. 106 (4)
Open AccessEndovascular treatment of systematic isolated mesenteric artery dissection with a patent false lumen: Bare stents alone versus stent-assisted coiling
Objectives: Bare stent treatment and bare stent-assisted coiling treatment have not been directly compared in symptomatic isolated superior mesenteric artery dissection with a patent false lumen. Thus, we compared the early and mid-term outcomes of bare stent treatment and bare stent-assisted coiling treatment to determine the most effective remedy for patients with this condition. Methods: Consecutive patients diagnosed with systematic isolated superior mesenteric artery dissection with a patent false lumen admitted to the study hospital between January 2016 and December 2021 were enrolled in this retrospective study. Their demographic data, clinical findings, treatment options, early outcomes, and follow-up results were analyzed. Results: A total of 85 patients (83 men) were included. 34.1% (n = 29) adopted bare stent treatment and 65.9% (n = 56) underwent bare stent-assisted coiling treatment. The symptoms were relieved in all patients (100%) with bare stent treatment and bare stent-assisted coiling treatment. There was no significant difference in the length of hospital stay between the two endovascular treatments ( p = 0.354). The cumulative complete remodeling rate was 100% in bare stent-assisted coiling treatment vs. 70.4% in bare stent treatment ( p < 0.0001). The prevalence of adverse events for abdominal pain recurrence (none in BST or bare stent-assisted coiling treatment), and formation of the aneurysm (two in bare stent treatment, and none in bare stent-assisted coiling treatment) showed no significant difference at follow-up. Conclusion: Both bare stent treatment and bare stent-assisted coiling treatment for symptomatic isolated superior mesenteric artery dissection with a patent false lumen have the same satisfying early outcome. In the midterm follow-up, bare stent-assisted coiling treatment has the higher cumulative complete remodeling rate which could be prioritized to treat this condition.
- 1 April 2022
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 81, 300-307
Outcomes of Covered Stents With Vacuum Sealing Drainage For Treatment of Infected Femoral Pseudoaneurysms in Intravenous Drug Addicts
- 1 April 2022
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 81, 300-307
Outcomes of Covered Stents With Vacuum Sealing Drainage For Treatment of Infected Femoral Pseudoaneurysms in Intravenous Drug Addicts
- Open Access
- 1 June 2020
- Published by Elsevier in The Lancet
- Vol. 395 (10240) , 1834
Increasing tobacco sales under the anti-smoking policy in China
- 1 June 2020
- Published by Elsevier in The Lancet
- Vol. 395 (10240) , 1834
Open AccessIncreasing tobacco sales under the anti-smoking policy in China
- 1 March 2020
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 59 (3) , 445
Inferior Vena Cava Filter Strut Fracture
- 1 March 2020
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 59 (3) , 445
Inferior Vena Cava Filter Strut Fracture
- 1 March 2020
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 59 (3) , 463
Peripherally Inserted Central Catheter in the Pulmonary Artery
- 1 March 2020
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 59 (3) , 463
Peripherally Inserted Central Catheter in the Pulmonary Artery
- Open Access
- 1 April 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (15) , e0312
Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer
This study aimed to explore the effect and toxicity of icotinib and whole-brain radiotherapy (IWBRT) for the treatment of brain metastases from nonsmall cell lung cancer (BMNSCLC) with epidermal growth factor receptor (EGFR)-mutant among Chinese Han population. A total of 55 patients with EGFR-mutant BMNSCLC were included. They received orally icotinib (125 mg/tablet, 125 mg each time, 3 times daily) until disease progression. In addition, they also underwent whole-brain radiotherapy (3-Gy fractions once daily, 5 days weekly for a total dose of 30 Gy) in an attempt to extend their survival time. The outcomes consisted of complete response (CR), partial response (PR), stable disease (SD), progress disease (PD), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). In addition, toxicity was also recorded in this study. The CR, PR, SD, PD, ORR, PFS, and OS were 38.2%, 52.8%, 5.4%, 3.6%, 90.1%, 12.5%, and 48.0% months, respectively. In addition, mild toxicity was observed in this study. This study demonstrated that IWBRT is efficacious with acceptable toxicity for patients with EGFR-mutant BMNSCLC among Chinese Han population.
- 1 April 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (15) , e0312
Open AccessIcotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer
This study aimed to explore the effect and toxicity of icotinib and whole-brain radiotherapy (IWBRT) for the treatment of brain metastases from nonsmall cell lung cancer (BMNSCLC) with epidermal growth factor receptor (EGFR)-mutant among Chinese Han population. A total of 55 patients with EGFR-mutant BMNSCLC were included. They received orally icotinib (125 mg/tablet, 125 mg each time, 3 times daily) until disease progression. In addition, they also underwent whole-brain radiotherapy (3-Gy fractions once daily, 5 days weekly for a total dose of 30 Gy) in an attempt to extend their survival time. The outcomes consisted of complete response (CR), partial response (PR), stable disease (SD), progress disease (PD), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). In addition, toxicity was also recorded in this study. The CR, PR, SD, PD, ORR, PFS, and OS were 38.2%, 52.8%, 5.4%, 3.6%, 90.1%, 12.5%, and 48.0% months, respectively. In addition, mild toxicity was observed in this study. This study demonstrated that IWBRT is efficacious with acceptable toxicity for patients with EGFR-mutant BMNSCLC among Chinese Han population.
- 13 October 2017
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 179 (1) , 95-100
CONSTRUCTION AND TEST OF A PORTABLE TISSUE-EQUIVALENT PROPORTIONAL COUNTER SYSTEM
Tissue-equivalent proportional counter (TEPC) is a very promising dosemeter for radiation protection in mixed radiation fields. In this article, a portable TEPC system including a spherical homemade TEPC detector and the compact low-power integrated circuit prototype was constructed and tested in gamma and neutron radiation fields. The microdosimetric spectra results displayed that the portable TEPC system could deal with four orders of magnitude voltage pulse signals. And the measured dose equivalent values agreed with reference values, which means the portable TEPC system had fulfilled the test and satisfied the requirement for radiation monitor.
- 13 October 2017
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 179 (1) , 95-100
CONSTRUCTION AND TEST OF A PORTABLE TISSUE-EQUIVALENT PROPORTIONAL COUNTER SYSTEM
Tissue-equivalent proportional counter (TEPC) is a very promising dosemeter for radiation protection in mixed radiation fields. In this article, a portable TEPC system including a spherical homemade TEPC detector and the compact low-power integrated circuit prototype was constructed and tested in gamma and neutron radiation fields. The microdosimetric spectra results displayed that the portable TEPC system could deal with four orders of magnitude voltage pulse signals. And the measured dose equivalent values agreed with reference values, which means the portable TEPC system had fulfilled the test and satisfied the requirement for radiation monitor.